New York, Jan 24, 2026, 17:24 EST — Market closed.
- Amgen shares slipped 0.7% to $344.75 on Friday, ending a six-day winning run.
- After hitting a new 52-week high on Thursday, the stock wrapped up the week with gains.
- Attention shifts to the Fed’s decision next week, along with Amgen’s Feb. 3 earnings call for updates on guidance and its pipeline.
Amgen Inc. shares dipped 0.7% on Friday, closing at $344.75. This halted a six-day winning streak, though the stock still stands roughly 4% higher than it was a week ago. (StockAnalysis)
The stock hit $349.98 on Thursday, pressing against the upper boundary of its 52-week range, which spans from $261.43 to $349.98, based on price data. (Investing)
Next week’s jam-packed schedule could quickly shift risk appetite. Investors are bracing for a Federal Reserve decision on Wednesday, plus a flood of quarterly earnings from major U.S. companies, according to a Reuters Week Ahead column. “At the end of the day, earnings are the driver,” said Chris Galipeau, senior market strategist at Franklin Templeton, in comments to Reuters. (Kitco)
Wall Street wrapped up a choppy week as the Dow slipped while the S&P 500 barely moved. Intel’s shares dropped after it warned of a dimmer outlook, and ongoing geopolitical tensions rattled investors, Reuters reported on Friday. (Reuters)
Amgen now faces the test of whether its stock rally can hold through earnings season. Investors are zeroing in on MariTide, its obesity drug candidate, pitched as a less frequent injection alternative to the weekly shots from Eli Lilly and Novo Nordisk. Amgen’s R&D head Jay Bradner told Reuters the company is “unambiguously in the lead” for monthly-or-less dosing. BMO analyst Evan Seigerman highlighted the maintenance use case as the key to the drug’s valuation. (Reuters)
In November, Amgen’s latest quarterly results surpassed expectations, prompting the company to raise its full-year earnings forecast. The boost came largely from higher sales of drugs like the cholesterol medication Repatha, Reuters reported. (Reuters)
The obesity program still poses a risk to sentiment. Previous MariTide studies reported significant weight loss but also gastrointestinal side effects. Investors are awaiting more detailed updates on tolerability and dosing from longer trials. (Reuters)
Income-focused investors are eyeing the dividend schedule closely. Amgen announced its board has approved a quarterly dividend of $2.52 per share. Shareholders on record by Feb. 13 will get the payment on March 6. (Amgen Investors)
Amgen’s next major company event is just around the corner. The biotech firm has scheduled its fourth-quarter 2025 earnings call for Tuesday, Feb. 3, at 1:30 p.m. PST, according to its investor relations calendar. (Amgen Investors)
